Pandion Therapeutics, Inc. logo
Pandion Therapeutics, Inc. PAND

Pandion Therapeutics, Inc. Long-Term Debt 2011-2026 | PAND

Long-term debt is a financial obligation of a company or an individual with a repayment period exceeding one year from the date it arises. In accounting, such obligations are recorded under the "long-term liabilities" section.

Main characteristics:
  • Term exceeds 12 months
  • Can take the form of bonds, bank loans, credit lines, leasing, or loans from affiliated parties
  • Repaid through regular payments (interest and/or principal) over several years
Why long-term debt is needed:
  • Investment in development
    Allows financing of large projects — new factories, production lines, innovative developments — without diverting working capital.
  • Smoothing of cash flows
    A long-term payment schedule facilitates budget planning and reduces short-term financial risks.
  • Optimization of capital structure
    A combination of equity and borrowed capital can reduce the average cost of business financing.

A high level of long-term debt may indicate that a company heavily relies on borrowed funds. This increases risks, especially in conditions of rising interest rates or declining profits. However, a moderate level of debt can signal a sound growth strategy — for example, the company takes a loan to expand its business.

If a company uses borrowed funds effectively (e.g., invests in profitable projects), this can lead to profit growth and, consequently, an increase in stock value. An investor evaluates whether the investments made using debt are paying off.

It is important to monitor whether the company can regularly pay interest and repay the principal. Payment difficulties can lead to reduced dividends, a drop in stock value, and even bankruptcy.

Examples of long-term debt:
  • Mortgage loans for property purchases
  • Corporate bonds issued by a company to raise capital
  • Project financing — long-term loans for building or expanding production facilities
  • Leasing obligations for equipment or transport

Annual Long-Term Debt Pandion Therapeutics, Inc.

2020 2019 2018 2017 2016 2015 2014 2013 2012 2011
- 3.68 M 2.01 M - - - - - - -

All numbers in USD currency

Indicator range from annual reports

Maximum Minimum Average
3.68 M 2.01 M 2.84 M

Long-Term Debt of other stocks in the Biotechnology industry

Issuer Long-Term Debt Price % 24h Market Cap Country
MorphoSys AG MorphoSys AG
MOR
273 M - 2.43 % $ 254 M germanyGermany
I-Mab I-Mab
IMAB
68.2 M - - $ 866 M chinaChina
Midatech Pharma plc Midatech Pharma plc
MTP
4.76 M - -18.52 % $ 27.3 M britainBritain
Alexion Pharmaceuticals, Inc. Alexion Pharmaceuticals, Inc.
ALXN
2.42 B - - $ 40.3 B usaUSA
Aptorum Group Limited Aptorum Group Limited
APM
130 K $ 0.89 - $ 6.54 M chinaChina
Biophytis SA Biophytis SA
BPTS
1.83 M - -13.47 % $ 169 M franceFrance
Genfit SA Genfit SA
GNFT
173 M - 2.54 % $ 160 B franceFrance
ACADIA Pharmaceuticals ACADIA Pharmaceuticals
ACAD
42 M $ 22.2 - $ 3.68 B usaUSA
EyeGate Pharmaceuticals, Inc. EyeGate Pharmaceuticals, Inc.
EYEG
278 K - -1.52 % $ 24.7 M usaUSA
Edesa Biotech Edesa Biotech
EDSA
19.8 K $ 15.9 - $ 50.8 M usaUSA
Applied Molecular Transport Applied Molecular Transport
AMTI
49 K - - $ 10.1 M usaUSA
Exelixis Exelixis
EXEL
173 M $ 44.69 - $ 12.1 B usaUSA
Advaxis Advaxis
ADXS
8.14 M - -9.65 % $ 45.9 M usaUSA
Институт стволовых клеток человека Институт стволовых клеток человека
ISKJ
175 M - - - russiaRussia
Grifols, S.A. Grifols, S.A.
GRFS
5.9 B $ 7.91 - $ 6.83 B spainSpain
Harmony Biosciences Holdings Harmony Biosciences Holdings
HRMY
144 M $ 31.05 - $ 1.79 B usaUSA
Aeterna Zentaris Aeterna Zentaris
AEZS
31 K - 5.93 % $ 314 M canadaCanada
AgeX Therapeutics AgeX Therapeutics
AGE
2.95 M - -10.17 % $ 12.2 K usaUSA
ImmuCell Corporation ImmuCell Corporation
ICCC
7.49 M $ 8.44 - $ 76.2 M usaUSA
Brainstorm Cell Therapeutics Brainstorm Cell Therapeutics
BCLI
171 K - -2.5 % $ 5.88 M usaUSA
BioNTech SE BioNTech SE
BNTX
231 M $ 101.57 - $ 27.2 B germanyGermany
Aeglea BioTherapeutics Aeglea BioTherapeutics
AGLE
4 M - - $ 1.01 B usaUSA
Immuron Limited Immuron Limited
IMRN
175 K $ 0.81 0.3 % $ 9.47 M australiaAustralia
Applied Genetic Technologies Corporation Applied Genetic Technologies Corporation
AGTC
9.12 M - - $ 26.5 M usaUSA
Incyte Corporation Incyte Corporation
INCY
30.2 M $ 99.1 - $ 19.3 B usaUSA
AIkido Pharma AIkido Pharma
AIKI
2.29 M - 1.93 % $ 17.4 M usaUSA
InMed Pharmaceuticals InMed Pharmaceuticals
INM
16 K $ 0.7 - $ 1.71 M canadaCanada
INmune Bio INmune Bio
INMB
411 K $ 1.33 - $ 32.9 M usaUSA
Innoviva Innoviva
INVA
258 M $ 23.05 - $ 1.55 B usaUSA
Akero Therapeutics Akero Therapeutics
AKRO
529 K - - $ 3.67 B usaUSA
Innate Pharma S.A. Innate Pharma S.A.
IPHA
16.9 M $ 1.48 -0.67 % $ 235 M franceFrance
Jaguar Health Jaguar Health
JAGX
892 K $ 7.88 - $ 18.4 M usaUSA
Akouos Akouos
AKUS
28.3 M - 0.23 % $ 488 M usaUSA
Allakos Allakos
ALLK
38.2 M - - $ 28.6 M usaUSA
KalVista Pharmaceuticals KalVista Pharmaceuticals
KALV
172 M $ 26.67 - $ 1.44 B britainBritain
AlloVir AlloVir
ALVR
1.13 M - 4.14 % $ 49.1 M usaUSA
Kamada Ltd. Kamada Ltd.
KMDA
36 K $ 8.11 - $ 260 M israelIsrael
Krystal Biotech Krystal Biotech
KRYS
7.57 M $ 259.95 - $ 7.52 B usaUSA
Ligand Pharmaceuticals Incorporated Ligand Pharmaceuticals Incorporated
LGND
49 K $ 224.86 - $ 4.11 B usaUSA
Ampio Pharmaceuticals Ampio Pharmaceuticals
AMPE
274 K - -11.43 % $ 502 K usaUSA
CureVac N.V. CureVac N.V.
CVAC
25.4 M - - $ 867 M germanyGermany
Liquidia Corporation Liquidia Corporation
LQDA
19.9 M $ 38.15 - $ 3.28 B usaUSA
Applied Therapeutics Applied Therapeutics
APLT
38 K - - $ 8.42 M usaUSA
Aptose Biosciences Aptose Biosciences
APTO
193 K - -45.71 % $ 1.2 M canadaCanada
Aquestive Therapeutics Aquestive Therapeutics
AQST
45 M $ 4.05 - $ 433 M usaUSA
Aptinyx Aptinyx
APTX
22.1 M - -39.0 % $ 4.57 M usaUSA